In-House Versus Outsource: A Decision-Making Guide

In-House Versus Outsource: A Decision-Making GuideThe biologics market is quickly evolving from a focus on developing blockbuster drugs to exploring niche markets with unmet needs. While the changes are exciting, they pose several risks to a molecule’s success as competition intensifies, timelines shorten and capacity challenges emerge. Yesterday’s solutions may not be a perfect fit for today’s molecules.

Barry Rosenblatt, PhD President, SME Biotech Consulting
Dave Kenyon, PhD Vice President, Process Sciences Pharma Services Patheon, by Thermo Fisher Scientific

Resource Library

Related Sites

Additional Resources